Introduction
============

Knee osteoarthritis (KOA) is a progressive joint disease that often involves intra- and periarticular structures \[[@pnz011-B1]\] and is considered pathology characterized by articular cartilage lesions, synovitis, subchondral sclerosis, and osteophytes \[[@pnz011-B2]\]. In addition, KOA is one of the most common causes of joint pain and loss of motor function among middle-aged and elderly people in the United States \[[@pnz011-B3],[@pnz011-B4]\]. Despite advances in medical technology, no drug or surgical intervention is currently available for delaying the development of KOA \[[@pnz011-B5]\]. Oral anti-inflammatory drugs, physiotherapy, topical anti-inflammatory gels, and intra-articular injections are currently routine treatments for patients with symptomatic KOA \[[@pnz011-B5],[@pnz011-B6]\]. Nonsurgical treatments, such as exercise and weight loss, are recommended because surgical treatment may lead to increased symptoms and poor functional outcomes \[[@pnz011-B7]\]. However, compliance with nonsurgical treatment is lower in KOA, and medications, such as simple analgesics and nonsteroidal anti-inflammatory drugs, are often associated with adverse events \[[@pnz011-B8],[@pnz011-B9]\]. Many studies have reported that hyaluronic acid (HA) has visco-induction properties and can increase intra-articular lubrication; therefore, intra-articular HA injection is widely used to treat KOA \[[@pnz011-B10]\]. However, although intra-articular drug therapy is often associated with reduced pain and increased joint function in patients, it is not effective in patients with KOA \[[@pnz011-B11]\].

In the past decade, the use of autologous growth factors to treat knee osteoarthritis, such as intra-articular injection of platelet-rich plasma (PRP), has received increasing attention \[[@pnz011-B12]\]. Recent studies have demonstrated that growth factors and other cytokines released by platelets during injury can modulate the inflammatory process and help maintain or regenerate tissue structure \[[@pnz011-B13],[@pnz011-B14]\]. The subchondral bone contributes to the cartilage repair process and KOA. PRP is an autologous blood product containing a high concentration of platelets, and it has become an emerging treatment for ligament, tendon, cartilage, and bone injuries in orthopedics and sports medicine \[[@pnz011-B15]\]. The intra-articular injection of PRP as a minimally invasive treatment has been widely used in the treatment of clinically related diseases. Sanchez et al. \[[@pnz011-B19]\] reported that a new technique for the delivery of PRP is intraosseous infiltration combined with intra-articular injections to treat severe KOA; moreover, no adverse reactions occurred in their study. Many clinical studies have reported good clinical efficacy of PRP injections \[[@pnz011-B20]\], and some previously published systematic reviews and meta-analyses have also suggested that PRP is a safe and effective orthopedic treatment compared with other intra-articular injections \[[@pnz011-B23]\]. However, these reviews did not reach a consensus in terms of the effects of PRP on pain relief and functional recovery and concluded that more high-quality randomized controlled trials (RCTs) are still needed. Previous reviews either included non-RCTs or only analyzed a small number of RCTs (\<10), and additional randomized trials have since been published. Therefore, further systematic reviews and meta-analyses are needed to fully investigate the effects of PRP on knee pain relief and functional improvement. Our aim is to identify all prospective RCTs published to date to provide up-to-date insights into the efficacy of PRP in the treatment of KOA.

Methods
=======

According to the PRISMA criteria, we created a prospective protocol including search strategies, selection criteria, outcome measurements, and methods of statistical analysis before commencing the study. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine. This review is registered in PROSPERO: CRD42018108825.

Search Strategy
---------------

A comprehensive search of the PubMed (1966--April 2018), EMBASE (1980--April 2018), and Cochrane library (1966--April 2018) databases was conducted. The search terms included "platelet-rich plasma," "PRP," "knee," "osteoarthritis," "arthritis," and "arthritic." No language exclusions were applied. Manual searches were performed on the references of the identified studies.

Selection Criteria
------------------

The inclusion criteria were as follows: 1) RCTs comparing PRP with HA as a treatment for patients with KOA and 2) data that include at least one key outcome indicator, including the Western Ontario and McMaster Universities Arthritis Index (WOMAC), International Knee Documentation Committee (IDKC), visual analog scale (VAS), Lequesne Index, or adverse events.

The exclusion criteria were as follows: 1) retrospective studies, cohort studies, or nonrandomized studies; 2) case reports, letters, editorials, and animal experimental studies; and 3) inability to extract relevant data from the included studies.

Data Extraction
---------------

Two authors (YHH and HTH) independently extracted relevant data from the included studies, including authors' names, publication date, patient age and gender, patient body mass index (BMI), sample size, radiographic classification, follow-up period, details of PRP treatment protocols and controls, and related clinical results. In the event that data were missing, we obtained detailed information by contacting the appropriate author.

Quality Assessment
------------------

Two authors (YHH and JKP) independently assessed the methodological quality of the included studies using the Cochrane Collaboration Tool for assessing the risk of bias (ROB). Each included study was scored as having a high, low, or unclear ROB according to the following evaluation criteria: 1) random sequence generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of outcome assessments, 5) incomplete outcome data, 6) selective reporting, and 7) other sources of bias. Any discrepancies between the reviewers' findings were arbitrated by the appropriate senior experts.

Statistical Analysis
--------------------

Review Manager 5.3.5 software (Cochrane Collaboration, Oxford, UK) was used for all analyses. Continuous data for the meta-analysis were calculated and are expressed as the mean differences (MDs) with 95% confidence intervals (CIs), and dichotomous data for the meta-analysis are presented as risk ratios (RRs) with 95% CIs. Heterogeneity between studies was estimated with the *I*^2^ test. If the heterogeneity was at an *I*^2^ value of 75% or higher, a random-effects model was used; otherwise, a fixed-effects model was used. *P* values \<0.05 were considered to indicate statistical significance in all the results.

Ethical Approval
----------------

This article does not contain any studies with human participants or animals performed by any of the authors.

Results
=======

Search Results
--------------

[Figure 1](#pnz011-F1){ref-type="fig"} shows the flow diagram of study selection. A total of 586 records were identified after the initial literature search. Of these, 296 records were excluded after a thorough screen of the titles and abstracts. Ultimately, the remaining 51 studies were assessed by performing a full-text review, and 15 RCTs \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B22],[@pnz011-B28]\] were included in the meta-analysis.

![Flow diagram of study selection.](pnz011f1){#pnz011-F1}

Study Characteristics
---------------------

[Table 1](#pnz011-T1){ref-type="table"} shows the characteristics of the included studies. The sample sizes of the studies ranged from 10 to 94, with a total of 1314 individuals; 643 individuals were included in the HA group and 671 individuals in the PRP group. One of the studies \[[@pnz011-B28]\] had a total follow-up period of three months, seven studies \[[@pnz011-B29],[@pnz011-B30],[@pnz011-B34],[@pnz011-B35],[@pnz011-B37]\] had follow-up periods of six months, six studies \[[@pnz011-B21],[@pnz011-B22],[@pnz011-B31],[@pnz011-B36]\] had follow-up periods of 12 months, and only one study \[[@pnz011-B2]\] had a follow-up period of 18 months. With the exception of one study \[[@pnz011-B37]\], all studies used the Kellgren and Lawrence grading scales to classify the severity of KOA. The patients in most studies had KOA with a severity of class II or III. The demographic characteristics between the two groups in each of the included studies were similar.

###### 

Characteristics of the included studies

  Author                                      Date   Sample Size   Gender (F/M)    Age, y   BMI, kg/m^2^   Radiographic Classification (K-L)   Follow-up Periods, mo   Clinical Outcomes                                                     
  ------------------------------------------- ------ ------------- -------------- -------- -------------- ----------------------------------- ----------------------- ------------------- ----------- ---------------- ---------------- ---- ---------------------------------------------
  Paterson et al. \[[@pnz011-B28]\]           2016   11            10               8/3         7/3                    49.9±13.7                     52.7±10.3             27.9±11.9       30.8±5.6   II, III          II, III          3    VAS, Adverse events
  Li et al. \[[@pnz011-B29]\]                 2011   15            15               6/9         7/8                      36∼76                         39∼76               19.4∼29.5       17.6∼28.9  I, II, III, IV   I, II, III, IV   6    WOMAC, IDKC, Lequesne Index, Adverse events
  Cerza et al. \[[@pnz011-B30]\]              2012   60            60              25/35       28/32                   66.5±11.3                     66.2±10.6                NA              NA      I, II, III       I, II, III       6    WOMAC, Adverse events
  Cole et al. \[[@pnz011-B31]\]               2017   49            50              28/21       20/30                   55.9±10.4                     56.8±10.5             27.4±3.9        29.0±6.4   I, II, III       I, II, III       12   VAS, WOMAC, IDKC
  Duymus et al. \[[@pnz011-B32]\]             2016   33            34               32/1        33/1                   60.4±5.1                      60.3±9.1              27.6±4.6        28.4±3.6   II, III          II, III          12   VAS, WOMAC
  Filardo et al. \[[@pnz011-B33]\]            2015   94            89              34/60       37/52                   53.3±13.2                     57.6±11.8             26.6±4.0        26.9±4.4   I, II, III       I, II, III       12   IDKC
  Gormeli et al. \[[@pnz011-B34]\]            2015   39            39              23/16       22/17                   57.3±13.1                      53.5±14              28.7±4.8        29.7±3.7   I, II, III, IV   I, II, III, IV   6    IDKC
  Montanez-Heredia et al. \[[@pnz011-B35]\]   2016   27            26              15/12        17/9                   66.3±8.3                      61.5±8.6              29.0±5.5        30.4±4.9   I, II, III       I, II, III       6    Adverse events
  Raeissadat et al. \[[@pnz011-B36]\]         2015   77            62               69/8       47/15                   56.9±9.1                      61.1±7.5              28.2±4.6        27.0±4.2   I, II, III, IV   I, II, III, IV   12   WOMAC
  Sanchez et al. \[[@pnz011-B37]\]            2012   79            74              46/33       45/29                   60.5±7.9                      58.9±8.2              27.9±2.9        28.2±2.7   NA               NA               6    WOMAC, Lequesne Index, Adverse events
  Vaquerizo et al. \[[@pnz011-B21]\]          2013   48            42              32/16       26/16                   62.4±6.6                      64.8±7.7              30.7±3.6        31.0±4.6   II, III, IV      II, III, IV      12   WOMAC, Lequesne Index, Adverse events
  Raeissadat et al. \[[@pnz011-B38]\]         2017   36            33               29/7        27/6                   57.0±7.2                      59.5±7.5              28.6±2.82       27.5±2.9   II, III          II, III          6    VAS, WOMAC, Adverse events
  Su et al. \[[@pnz011-B2]\]                  2018   25            30              14/11       18/12                   54.2±6.6                      53.1±6.4              28.2±1.4        28.7±1.1   II, III          II, III          18   VAS, WOMAC, Adverse events
  Filardo et al. \[[@pnz011-B22]\]            2012   54            55              17/37       24/31                      55                            58                    27              26      I, II, III       I, II, III       12   IDKC
  Louis et al. \[[@pnz011-B39]\]              2018   24            24              10/14       13/11                   53.2±11.7                     48.5±11.5             25.6±2.9        27.0±2.9   III, IV          III, IV          6    VAS, WOMAC, Adverse events

BMI = body mass index; HA = hyaluronic acid; IDKC = International Knee Documentation Committee; K-L = Kellgren and Lawrence grading scale; NA = data not available; PRP = platelet-rich plasma; VAS = visual analog scale, WOMAC = Western Ontario and McMaster Universities Arthritis Index.

The preparation and administration of PRP varied among these studies. [Table 2](#pnz011-T2){ref-type="table"} shows the details of PRP preparation and administration protocols specific to each included study, such as the PRP category, the use of exogenous activators, and the injection regimen, including the doses, times, and intervals.

###### 

Details of the PRP treatment protocols and the controls

  Author                                      Date   PRP      HA                                                                                         
  ------------------------------------------- ------ -------- ---------------------------- --------------------------- ------------------ -------------- ------------------------
  Paterson et al. \[[@pnz011-B28]\]           2016   PA-PRP   Ultraviolet light            3 mL, 3 times, weekly       Fresh              Hylan G-F 20   3 mL, 3 times, weekly
  Li et al. \[[@pnz011-B29]\]                 2011   PRP      Calcium chloride             3.5 mL, 3 times, 3 weeks    Fresh              Sofast         2 mL, 3 times, 3 weeks
  Cerza et al. \[[@pnz011-B30]\]              2012   ACP      NA                           5.5 mL, 4 times, weekly     Fresh              Hyalgan        20 mg, 4 times, weekly
  Cole et al. \[[@pnz011-B31]\]               2017   PRP      NA                           4 mL, 3 times, weekly       Fresh              Hylan G-F 20   16 mg, 3 times, weekly
  Duymus et al. \[[@pnz011-B32]\]             2016   PRP      NO                           5 mL, 2 times, monthly      Fresh              Ostenil Plus   40 mg, 1 time, monthly
  Filardo et al. \[[@pnz011-B33]\]            2015   PRP      10% calcium chloride         5 mL, 3 times, weekly       Fresh              Hyalubrix      30 mg, 3 times, weekly
  Gormeli et al. \[[@pnz011-B34]\]            2015   PRP      1 mL of calcium chloride     5 mL, 3 times, weekly       1 fresh/2 frozen   Orthovisc      2 mL, 3 times, weekly
  Montanez-Heredia et al. \[[@pnz011-B35]\]   2016   PRP      NA                           NA, 3 times, 15 days        Frozen             Adant          NA, 3 times, 15 days
  Raeissadat et al. \[[@pnz011-B36]\]         2015   LR-PRP   NO                           4--6 mL, 2 times, 4 weeks   Fresh              Hyalgan        20 mg, 3 times, weekly
  Sanchez et al. \[[@pnz011-B37]\]            2012   PRGF     400 uL of calcium chloride   8 mL, 3 times, weekly       Fresh              Euflexxa       NA, 3 times, weekly
  Vaquerizo et al. \[[@pnz011-B21]\]          2013   PRGF     400 uL of calcium chloride   8 mL, 3 times, weekly       Fresh              Durolane       NA, 1 time
  Raeissadat et al. \[[@pnz011-B38]\]         2017   PRGF     1.5 mL of Rooyagen           5 mL, 2 times, 3 weeks      Fresh              Hyalgan        20 mg, 3 times, weekly
  Su et al. \[[@pnz011-B2]\]                  2018   LR-PRP   Calcium chloride             6 mL, 2 times, 14 days      Fresh              Freda          2 mL, 5 times, weekly
  Filardo et al. \[[@pnz011-B22]\]            2012   PRP      NA                           5 mL, 3 times, weekly       Frozen             Hyalubrix      NA, 3 times, weekly
  Louis et al. \[[@pnz011-B39]\]              2018   PRP      Calcium chloride             3 mL, 1 time                Fresh              Durolane       3 mL, 1 time

ACP = autologous conditioned plasma; HA = hyaluronic acid; LP-PRP = leukocyte-poor platelet-rich PRP; LR-PRP = leukocyte-rich platelet-rich PRP; NA = data not available; NO = No Activation; PA-PRP = photo-activation and platelet-rich plasma; PRGF = plasma rich in growth factors; PRP = platelet-rich plasma.

Assessment of the ROB
---------------------

The summary of the ROB assessment of all included studies is illustrated in [Figure 2](#pnz011-F2){ref-type="fig"}. Adequate randomized sequences were generated in 13 studies \[[@pnz011-B2],[@pnz011-B19],[@pnz011-B22],[@pnz011-B28],[@pnz011-B31]\]. However, two studies \[[@pnz011-B29],[@pnz011-B30]\] referred to random assignments but did not report the details of these random assignments. Appropriate allocation concealment was reported in eight studies \[[@pnz011-B21],[@pnz011-B22],[@pnz011-B28],[@pnz011-B31],[@pnz011-B33],[@pnz011-B34],[@pnz011-B37],[@pnz011-B39]\], the blinding of participants and personnel was clear in nine studies \[[@pnz011-B21],[@pnz011-B22],[@pnz011-B28],[@pnz011-B31],[@pnz011-B33],[@pnz011-B34],[@pnz011-B37]\], and the blinding of outcome assessors was reported in eight studies \[[@pnz011-B21],[@pnz011-B22],[@pnz011-B33],[@pnz011-B37]\]. Incomplete outcome data were not observed in all included studies. In addition, no selective reporting or other obvious sources of bias were identified in these studies.

![Risk of bias assessment.](pnz011f2){#pnz011-F2}

Outcomes of the Meta-analysis
=============================

WOMAC Pain Score
----------------

WOMAC pain scores were reported by three \[[@pnz011-B2],[@pnz011-B31],[@pnz011-B32]\], four \[[@pnz011-B2],[@pnz011-B31],[@pnz011-B32],[@pnz011-B39]\], six \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B31],[@pnz011-B32],[@pnz011-B37],[@pnz011-B38]\], and five studies \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B31],[@pnz011-B32],[@pnz011-B36]\] at one, three, six, and 12 months, respectively. The pooled analysis did not reveal significant differences between the PRP and HA groups at one (MD = −0.19, 95% CI = −0.65 to 0.27, *I*^2^ = 67%, *P* = 0.42) and three months (MD = −0.31, 95% CI = −1.16 to 0.54, *I*^2^ = 88%, *P* = 0.47). However, subjects in the PRP group experienced significantly more pain relief than those in the HA group at six (MD = −1.24, 95% CI = --1.94 to −0.53, *I*^2^ = 83%, *P* = 0.0006) and 12 months (MD = −1.75, 95% CI = −2.50 to −1.01, *I*^2^ = 89%, *P* \< 0.000001). [Table 3](#pnz011-T3){ref-type="table"} presents all of these details.

###### 

Details of PRP treatment protocols and control

  Follow-up, mo   WOMAC    No. of Studies   No. of Cases PRP/HA           MD               (95% CI)        Heterogeneity, *P*; *I*^2^   *P* Value of Effect Size, Z (*P*)
  --------------- ------- ---------------- --------------------- -------------------- ------------------- ---------------------------- -----------------------------------
  1               Pain           3                108/114                 --           (--0.65 to 0.27)            0.05; 67%                       0.80 (0.42)
  Stiffness       2            58/64               −0.13           (--0.41 to 0.15)        0.21; 35%              0.89 (0.37)          
  Function        2            58/64               −2.35           (--5.28 to 0.57)        0.12; 59%              1.57 (0.12)          
  Total           3           119/124              −3.81           (--7.98 to 0.36)        0.03; 71%              1.79 (0.07)          
  3               Pain           4                129/138               −0.31          (--1.16 to 0.54)          \<0.0001; 88%                     0.72 (0.47)
  Stiffness       3            80/88               −0.35          (--0.63 to −0.08)        0.44; 0%               2.50 (0.01)          
  Function        4            80/88               −1.92          (--2.57 to −1.27)        0.80; 0%            5.82 (\<0.000001)       
  Total           5           155/163              −5.02          (--10.79 to 0.76)     \<0.00001; 89%            1.70 (0.09)          
  6               Pain           6                270/263               −1.24          (--1.94 to −0.53)         \<0.0001; 83%                    3.42 (0.0006)
  Stiffness       5           221/213              −0.46           (--0.92 to 0.01)        0.04; 60%              1.93 (0.05)          
  Function        5           221/213              −3.71          (--7.21 to −0.22)      \<0.0001; 84%            2.08 (0.04)          
  Total           7           296/288             −10.78          (--17.51 to −4.04)    \<0.00001; 94%            3.13 (0.002)         
  12              Pain           5                232/218               −1.75          (--2.50 to −1.01)         \<0.00001; 89%                 4.61 (\<0.000001)
  Stiffness       4           183/168              −0.99          (--1.57 to −0.42)       0.001; 81%             3.40 (0.0007)         
  Function        4           183/168              −8.90          (--14.82 to −2.99)    \<0.00001; 94%            2.95 (0.003)         
  Total           4           183/168             −12.11          (--20.21 to −4.01)    \<0.00001; 94%            2.93 (0.003)         

WOMAC Stiffness Score
---------------------

WOMAC stiffness scores were reported by two \[[@pnz011-B2],[@pnz011-B32]\], three \[[@pnz011-B2],[@pnz011-B32],[@pnz011-B39]\], five \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B32],[@pnz011-B37],[@pnz011-B38]\], and four studies \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B32],[@pnz011-B36]\] at one, three, six, and 12 months, respectively. The pooled analysis did not reveal significant differences between the PRP and HA groups at one (MD = −0.13, 95% CI = −0.41 to 0.15, *I*^2^ = 35%, *P* = 0.37) and six months (MD = −0.46, 95% CI = −0.92 to 0.01, *I*^2^ = 60%, *P* = 0.05). However, the subjects in the PRP group experienced significantly greater improvement in knee stiffness than those in the HA group at three (MD = --0.35, 95% CI = −0.63 to −0.08, *I*^2^ = 0%, *P* = 0.01) and 12 months (MD = −0.99, 95% CI = −1.57 to −0.42, *I*^2^ = 81%, *P* = 0.0007). [Table 3](#pnz011-T3){ref-type="table"} presents all of these details.

WOMAC Function Score
--------------------

WOMAC function scores were reported by two \[[@pnz011-B2],[@pnz011-B32]\], three \[[@pnz011-B2],[@pnz011-B32],[@pnz011-B39]\], five \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B32],[@pnz011-B37],[@pnz011-B38]\], and four studies \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B32],[@pnz011-B36]\] at one, three, six, and 12 months, respectively. The pooled analysis showed that the subjects in the PRP and HA groups exhibited similar functional recovery after one month (MD = −2.35, 95% CI = −5.28 to 0.57, *I*^2^ = 59%, *P* = 0.12) of treatment. However, the subjects in the PRP group performed better than those in the HA group at three (MD = −1.92, 95% CI = −2.57 to −1.27, *I*^2^ = 0%, *P* \< 0.000001), six (MD = −3.71, 95% CI = −7.21 to −0.22, *I*^2^ = 84%, *P* = 0.04), and 12 months (MD = −8.90, 95% CI = −14.82 to −2.99, *I*^2^ = 94%, *P* = 0.003). [Table 3](#pnz011-T3){ref-type="table"} presents all of these details.

WOMAC Total Score
-----------------

WOMAC total scores were reported by three \[[@pnz011-B2],[@pnz011-B30],[@pnz011-B32]\], five \[[@pnz011-B2],[@pnz011-B29],[@pnz011-B30],[@pnz011-B32],[@pnz011-B39]\], seven \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B29],[@pnz011-B30],[@pnz011-B32],[@pnz011-B37],[@pnz011-B38]\], and four studies \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B32],[@pnz011-B36]\] at one, three, six, and 12 months, respectively. The pooled analysis did not identify significant differences between the PRP and HA groups at one (MD = −3.81, 95% CI = −7.98 to 0.36, *I*^2^ = 71%, *P* = 0.07) and three months (MD = −5.02, 95% CI = −10.79 to 0.76, *I*^2^ = 89%, *P* = 0.09). However, the subjects in the PRP group experienced significantly greater improvement in total scores than those in the HA group at six (MD = −10.78, 95% CI = −17.51 to −4.04, *I*^2^ = 94%, *P* = 0.002) and 12 months (MD = −12.11, 95% CI = −20.21 to −4.01, *I*^2^ = 94%, *P* = 0.003). All these details are presented in [Table 3](#pnz011-T3){ref-type="table"}.

VAS
---

VAS scores for pain were reported by three \[[@pnz011-B28],[@pnz011-B32]\], four \[[@pnz011-B2],[@pnz011-B28],[@pnz011-B32],[@pnz011-B39]\], four \[[@pnz011-B2],[@pnz011-B31],[@pnz011-B32],[@pnz011-B38]\], and three studies \[[@pnz011-B2],[@pnz011-B31],[@pnz011-B32]\] at one, three, six, and 12 months, respectively. Therefore, a subgroup meta-analysis was performed to compare the VAS scores for pain based on the length of follow-up. No significant differences were observed between the PRP and HA groups at one (MD = 0.01, 95% CI = −0.13 to 0.15, *I*^2^ = 0%, *P* = 0.89), three (MD = −0.20, 95% CI = −0.64 to 0.24, *I*^2^ = 58%, *P* = 0.38), and six months (MD = −3.62, 95% CI = −7.49 to 0.26, *I*^2^ = 99%, *P* = 0.07). However, the treatment in the PRP groups exhibited better efficacy than that in the HA groups at 12 months (MD = −4.95, 95% CI = −7.83 to −2.06, *I*^2^ = 99%, *P* = 0.0008) ([Figure 3](#pnz011-F3){ref-type="fig"}).

![Forest plot and meta-analysis of VAS score.](pnz011f3){#pnz011-F3}

IDKC
----

IDKC scores were reported by two \[[@pnz011-B22],[@pnz011-B33]\], five \[[@pnz011-B22],[@pnz011-B29],[@pnz011-B31],[@pnz011-B33],[@pnz011-B34]\], and three studies \[[@pnz011-B22],[@pnz011-B31],[@pnz011-B33]\] at two, six, and 12 months, respectively. Therefore, a subgroup meta-analysis was performed to compare the IDKC scores based on the length of follow-up. No significant differences were observed between the PRP and HA groups at two (MD = 0.29, 95% CI = −3.44 to 4.02, *I*^2^ = 0%, *P* = 0.88) and 12 months (MD = 5.84, 95% CI = −1.05 to 12.72, *I*^2^ = 87%, *P* = 0.10). However, the subjects in the PRP group had significantly better IDKC scores than those in the HA group at six months (MD = 8.02, 95% CI = 4.13 to 11.91, *I*^2^ = 77%, *P* \< 0.0001) ([Figure 4](#pnz011-F4){ref-type="fig"}).

![Forest plot and meta-analysis of IDKC.](pnz011f4){#pnz011-F4}

Lequesne Index
--------------

Lequesne Index scores were reported by three studies \[[@pnz011-B21],[@pnz011-B29],[@pnz011-B37]\], with 142 patients treated with PRP and 131 with HA. The pooled analysis did not reveal a significant difference between the PRP and HA groups at six months (MD = −1.31, 95% CI = −3.50 to 0.89, *I*^2^ = 90%, *P* = 0.24) ([Figure 5](#pnz011-F5){ref-type="fig"}).

![Forest plot and meta-analysis of Lequesne index scores.](pnz011f5){#pnz011-F5}

Adverse Events
--------------

Adverse events were reported by nine studies \[[@pnz011-B2],[@pnz011-B21],[@pnz011-B28],[@pnz011-B35],[@pnz011-B37]\], with 323 patients treated with PRP and 314 with HA. The pooled analysis did not detect a significant difference between the PRP and HA groups (RR = 1.20, 95% CI = 0.91 to 1.58, *I*^2^ = 13%, *P* = 0.20) ([Figure 6](#pnz011-F6){ref-type="fig"}).

![Forest plot and meta-analysis of adverse events.](pnz011f6){#pnz011-F6}

Discussion
----------

As a common degenerative joint disease, KOA is the second leading cause of loss of joint function \[[@pnz011-B4]\], which causes enormous economic and social burdens worldwide \[[@pnz011-B40]\]. The understanding of KOA in terms of etiology and pathogenesis remains unclear \[[@pnz011-B41]\]; the main pathological changes involve components around the joints and degeneration of articular cartilage \[[@pnz011-B42]\].

HA is mainly composed of important factors such as D-glucosamine and N-acetyl-D-glucosamine, and these factors play an important role in nourishing cartilage and protecting joints \[[@pnz011-B43]\]. HA is degraded and diluted by exudates, resulting in a decrease in the molecular weight and endogenous concentration of HA in the knee joint cavity of patients with KOA. These changes reduce the viscoelasticity of the knee cartilage and reduce the knee's ability to resist mechanical stress and damage \[[@pnz011-B11],[@pnz011-B44]\]. Many clinical studies have also shown that HA can effectively relieve knee pain and improve knee function \[[@pnz011-B45]\]. However, some researchers have shown that HA does not improve regeneration of damaged cartilage, particularly in elderly patients with severe KOA \[[@pnz011-B44],[@pnz011-B48]\]. PRP is highly concentrated autologous plasma containing a variety of growth factors that promote the healing of ligaments, tendons, and bones, including platelet-derived growth factor, transforming growth factor--b, vascular endothelial growth factor, basic fibroblast growth factor, and bioactive proteins \[[@pnz011-B49]\]. As a vector for large growth factors \[[@pnz011-B52]\], PRP promotes tissue repair \[[@pnz011-B53]\] and is increasingly used to treat KOA. PRP plays an important role in mesenchymal stem cell proliferation and cartilage formation through a combination of various growth factors \[[@pnz011-B54]\]. It has been reported that PRP may have a positive effect on inducing migration, proliferation, and differentiation of precursor cells in cartilage. Therefore, PRP can effectively repair the damaged cartilage of the knee joint \[[@pnz011-B55]\] while reducing the effects of knee pain and inflammatory responses \[[@pnz011-B56]\]. These effects of PRP make it a new drug treatment for KOA.

Most of the previous systematic reviews have shown that PRP is an effective alternative treatment for long-term relief of knee pain and improved joint function in KOA patients. However, the previous conclusions were reached on the basis of a small number of RCTs \[[@pnz011-B23],[@pnz011-B27],[@pnz011-B57]\], and thus, the time effect of PRP injection therapy on KOA has not been fully investigated. Chang et al. \[[@pnz011-B58]\] found that patients receiving PRP injections showed better, longer-lasting improvements than patients receiving HA treatment; however, most of the studies that were included in the analysis were case series, and only five were RCTs. Laudy et al. \[[@pnz011-B27]\] pooled 10 trials, including six RCTs, and found that PRP injections were more effective than placebo or HA injections for alleviating pain symptoms and improving joint motor function in KOA patients. Another recent meta-analysis \[[@pnz011-B11]\] included 13 studies (10 RCTs) and synthesized the WOMAC scores to compare the efficacy of PRP injections with that of HA injections. Based on a large number of RCTs, this study evaluated the effects of PRP treatment on knee joint pain and physiological function at different times after injection.

In our study, the data from 15 RCTs showed that long-term pain relief and functional improvement in the PRP group were superior to those in the HA group. Divergent results were observed in the WOMAC, VAS, IKDC, and Lequesne Index scores, as well as in the occurrence of adverse events. The principal findings of this study were that within one to three months postinjection, subjects in the PRP group and HA group had similar experiences with respect to pain relief (WOMAC pain score and VAS pain score) and functional improvement (WOMAC total score, WOMAC function score, and IKDC score). In addition, no significant differences in the Lequesne Index were observed between the PRP and HA groups after six months. However, subjects in the PRP group experienced significantly better pain relief (WOMAC pain score and VAS pain score) and functional improvement (WOMAC function score, WOMAC total score, and IKDC score) between six and 12 months postinjection than those in the HA group. In addition, the HA and PRP groups did not display different adverse event rates.

Heterogeneity was different between all measured parameters, indicating that the effects were inconsistent throughout the studies. Based on a careful review and evaluation of all included studies, we found some common problems. First, the pathology of KOA in the PRP and HA groups was different among all these included studies, and the distribution of KOA severity among the studies varied between grades I and IV (K-L grading scale). As shown in the studies by Chang et al. \[[@pnz011-B58]\] and Filardo et al. \[[@pnz011-B59]\], PRP has a better effect on patients with early or moderate forms of KOA but has a limited effect on patients with advanced forms of KOA. Therefore, patients with different stages of KOA may not exhibit the same responses to PRP or HA treatment \[[@pnz011-B11]\].

Additionally, the number of injections and the length of the time between the two injections also varied among all these included studies. Among the studies that included multiple injections, an interval of two weeks was used in the studies by Montanez-Heredia et al. \[[@pnz011-B35]\] and Su et al. \[[@pnz011-B2]\], three weeks was adopted by Li et al. \[[@pnz011-B29]\] and Raeissadat et al. \[[@pnz011-B38]\], and one month was adopted by Duymus et al. \[[@pnz011-B32]\] and Raeissadat et al. \[[@pnz011-B36]\]. In the study by Gormeli et al. \[[@pnz011-B34]\], no differences were observed between patients who received an HA injection and those who received a single-dose PRP injection, whereas the patients receiving multiple-dose PRP experienced greater improvement than the patients receiving either of the other two treatments. However, Patel et al. \[[@pnz011-B53]\] concluded that a single dose of PRP injection and a double dose of PRP injection had the same therapeutic effect. The study by Görmeli et al. \[[@pnz011-B34]\] further confirmed this conclusion in patients with advanced KOA, as there was no difference between treatment methods. These findings might provide guidance for future treatment options, because a consensus regarding treatment methods is currently unavailable.

As this study was a systematic review, it inevitably had certain limitations. Limitations exist in the recommendation of routine PRP injections as a treatment for KOA because the composition of PRP remains uncertain. Different types of PRP preparations have been used; thus, these preparations differ in the platelet counts, growth factor concentrations, and leukocyte counts depending on the patient characteristics and the preparation kit. Furthermore, the interval between injections and the optimal dosage are still areas of concern in the future because they might exert an effect on the postinjection process, and there are currently no published studies supporting any specific injection protocol. In the present study, insufficient data were available for us to conduct a subgroup analysis to confirm whether multiple injections are necessary for patients with different stages of KOA.

Conclusions
===========

Based on the current evidence, the use of PRP to treat KOA has a positive effect on pain levels and functional outcomes. In addition, PRP injections do not display different adverse event rates compared with HA injections. There is a lack of clarity regarding the number and frequency of PRP injections required to achieve maximum results and in the ideal treatment regimens for different severities of KOA.
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